Imagine uncovering a hidden warning sign in your bloodwork that could predict devastating health crises like kidney failure or heart disease – yet it's often overlooked by medical professionals. This startling revelation comes from groundbreaking research, and it's one that could change how we approach kidney health forever. But here's where it gets controversial: even as these findings demand attention, many healthcare systems are slow to adopt the necessary testing. Stick with me as we dive into the details of this eye-opening study, and you'll see why this gap in kidney function assessments might just be the missing puzzle piece in preventing serious illnesses.
For years, doctors have relied on measuring creatinine levels in the blood to gauge how effectively the kidneys are filtering out waste from the breakdown of muscle tissue. Think of creatinine as a byproduct of your body's daily wear and tear – it's produced in muscles and should be cleared by healthy kidneys. However, newer guidelines suggest incorporating cystatin C, a tiny protein generated by all cells in the body, as another reliable marker for kidney function. The beauty of using both is that they account for different influences, such as age-related changes, certain diseases, or even lifestyle factors like smoking or obesity, providing a more comprehensive picture of kidney health. Alone, each test has its limitations, but together, they offer a fuller view that could spot risks earlier than ever before.
Led by experts at NYU Langone Health, this new research shines a light on a concerning trend: many individuals, particularly those who are ill, exhibit a significant disparity between these two test results. In a worldwide study, over a third of hospitalized participants showed cystatin C readings that were at least 30% lower than their creatinine-based estimates of kidney filtration rates. This isn't just a number crunching exercise – it's a potential red flag for future problems.
"Our findings highlight the importance of measuring both creatinine and cystatin C to gain a true understanding of how well the kidneys are working, particularly among older and sicker adults," explained study co-corresponding author Morgan Grams, MD, PhD. "Evaluating both biomarkers may identify far more people with poor kidney function, and earlier in the disease process, by covering the blind spots that go with either test." And this is the part most people miss: by catching these issues sooner, we could intervene before they escalate, potentially saving lives and reducing the need for extreme treatments.
The study, published online on November 7 in the Journal of the American Medical Association, was also presented at the American Society of Nephrology's annual Kidney Week conference. But why does this matter beyond just detecting disease? Grams, who holds the Susan and Morris Mark Professorship of Medicine at NYU Grossman School of Medicine, points out that accurate kidney function estimates are crucial for prescribing the right doses of medications – from cancer drugs to antibiotics. Imagine a patient on chemotherapy: if their kidney function is underestimated, they might receive too much of a drug, leading to toxic side effects. On the flip side, overestimating could mean ineffective treatment. This dual-test approach ensures safer, more personalized care.
In a related investigation, released on the same day, the same team revealed a sobering statistic: chronic kidney disease (CKD) – a long-term condition where kidneys don't filter blood as they should, often due to diabetes, high blood pressure, or other issues – has reached record global levels, now ranking as the ninth leading cause of death worldwide. CKD can sneak up quietly, causing symptoms like fatigue or swelling only in advanced stages, which is why early detection is key. By using both tests, we might prevent the need for drastic measures like dialysis, where a machine takes over kidney duties, or even kidney transplants from donors. Grams, also a professor in the Department of Population Health at NYU Grossman School of Medicine, emphasizes that earlier intervention could mean lifestyle changes, medications, or monitoring that keeps patients healthier longer.
To reach these conclusions, the researchers delved into a massive dataset from 860,966 participants across multiple nationalities, analyzing healthcare records, blood tests, and demographic details. Everyone had both creatinine and cystatin C measured on the same day, with follow-ups averaging 11 years. They factored in non-kidney influences like body weight, smoking habits, and cancer history to ensure accuracy. As part of the Chronic Kidney Disease Prognosis Consortium – an international effort to better understand and combat CKD – this is the largest study yet comparing these tests and linking discrepancies to health risks. The consortium's work informs global standards for defining CKD and its dangers, helping doctors worldwide.
The results are clear: individuals whose cystatin C-based kidney filtration estimates were at least 30% below their creatinine readings faced elevated risks of death, heart disease, and heart failure compared to those with smaller gaps. They were also more prone to severe CKD requiring dialysis or transplants. Surprisingly, this pattern held for 11% of outpatients and even seemingly healthy volunteers, broadening the implications far beyond hospitals.
But here's another layer of controversy: despite recommendations from Kidney Disease: Improving Global Outcomes (KDIGO) back in 2012, cystatin C testing remains underutilized. A 2019 survey showed fewer than 10% of U.S. clinical labs offered it in-house, though giants like Quest Diagnostics and Labcorp now provide it. "These results underscore the need for physicians to take advantage of the fact that more hospitals and health care providers are starting to offer cystatin C testing," said co-corresponding author Josef Coresh, MD, PhD, director of NYU Langone's Optimal Aging Institute. "Physicians might otherwise miss out on valuable information about their patients' well-being and future medical concerns." Coresh, who is also the Terry and Mel Karmazin Professor of Population Health at NYU Grossman School of Medicine, noted that among hospitalized Americans in the study, less than 1% underwent cystatin C testing – a statistic that raises questions about whether cost, availability, or inertia in medical practices is holding back progress. Is it fair that this potentially life-saving test isn't routine? And what if prioritizing it could reduce healthcare disparities, especially for underserved communities?
Funding came from a National Institutes of Health grant (R01DK100446) and the National Kidney Foundation, underscoring the importance of this work.
The study's first author is Michelle Estrella, MD, MHS, from the University of California, San Francisco, with Kai-Uwe Eckardt, MD, from Charité-Universitätsmedizin Berlin in Germany, as the last author. Co-leaders Grams and Coresh, along with NYU Langone researchers Shoshana Ballew, PhD; Yingying Sang, MS; and Aditya Surapaneni, PhD, collaborated with experts like Teresa Chen, MD, MHS, and Michael Shlipak, MD, MPH, from the University of California, San Francisco; Natalia Alencar de Pinho, PhD, from Paris-Saclay University in France; Johan Ärnlöv, MD, PhD, from Dalarna University in Sweden; Hermann Brenner, MD, MPH, from Heidelberg University in Germany; Juan-Jesús Carrero, PharmD, PhD, from Karolinska Institutet in Sweden; Debbie Cohen, MBBCh, from the University of Pennsylvania; Mary Cushman, MD, MSc, from the University of Vermont; Ron Gansevoort, MD, PhD, from the University of Groningen in the Netherlands; Shih-Jen Hwang, PhD, from the National Institutes of Health; Lesley Inker, MD, and Andrew Levey, MD, from Tufts Medical Center; Joachim Ix, MD, from the University of California, San Diego; Keiko Kabasawa, MD, PhD, MPH, from Niigata University in Japan; Tsuneo Konta, MD, PhD, from Yamagata University in Japan; Jennifer Lees, PhD, from the University of Glasgow in Scotland; Kevan Polkinghorne, PhD, from Monash University in Australia; Robin Vernooij, MS, from Utrecht University in the Netherlands; David Wheeler, MD, from University College London; and Ashok Kumar Yadav, PhD, from the Postgraduate Institute of Medical Education and Research in India.
About NYU Langone Health
NYU Langone Health stands as a fully integrated healthcare system renowned for delivering top-tier patient outcomes through an unwavering commitment to quality, achieving some of the nation's lowest mortality rates. Vizient, Inc., has recognized NYU Langone as the top comprehensive academic medical center out of 118 across the U.S. for four consecutive years, while U.S. News & World Report has ranked four of its specialties as number one in the nation. Offering a wide array of medical services under one consistent standard of care, NYU Langone operates seven inpatient facilities, the Perlmutter Cancer Center, and over 320 outpatient sites in New York and Florida. It also encompasses two tuition-free medical schools in Manhattan and on Long Island, plus a robust research network.
Media Inquiries
Shira Polan
Phone: 212-404-4279
shira.polan@nyulangone.org
SOURCE NYU Grossman School of Medicine and NYU Langone Health
What do you think? Should cystatin C testing be standard practice everywhere, or are there valid reasons to hesitate, like cost or logistical challenges? Do you believe this could revolutionize kidney care, or is it just another layer of complexity in an already overburdened system? Share your thoughts in the comments – I'd love to hear your take!
